Liraglutide Improves Blood Sugar, Body Composition, and Metabolic Health

Liraglutide treatment improved glycemic dysregulation and body composition, demonstrating comprehensive metabolic benefits of GLP-1 receptor activation.

Apperley, Louise et al.·Journal of clinical research in pediatric endocrinology·2025·Moderate Evidencecohort
RPEP-09958CohortModerate Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
cohort
Evidence
Moderate Evidence
Sample
N=not specified
Participants
Adolescents aged 12-17.9 years with severe obesity

What This Study Found

Liraglutide treatment improved glycemic dysregulation and body composition, demonstrating comprehensive metabolic benefits of GLP-1 receptor activation.

Key Numbers

Patients aged 12 to 17.9 years with severe obesity. Glycemic control assessed by continuous glucose monitoring (CGM).

How They Did This

In publication.

Why This Research Matters

Relevant to peptide therapeutics.

The Bigger Picture

Advances peptide evidence.

What This Study Doesn't Tell Us

In publication.

Questions This Raises

  • ?Long-term implications?
  • ?Evidence comparison?
  • ?Next steps?

Trust & Context

Key Stat:
Key finding Liraglutide treatment improved glycemic dysregulation and body composition, demonstrating comprehens
Evidence Grade:
Based on design.
Study Age:
Published in 2025.
Original Title:
Liraglutide Treatment Improves Glycaemic Dysregulation, Body Composition, Cardiometabolic Variables and Uncontrolled Eating Behaviour in Adolescents with Severe Obesity.
Published In:
Journal of clinical research in pediatric endocrinology, 17(1), 68-75 (2025)
Database ID:
RPEP-09958

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What does this mean?

Liraglutide treatment improved glycemic dysregulation and body composition, demonstrating comprehensive metabolic benefits of GLP-1 receptor activation.

How reliable?

Consult publication.

Read More on RethinkPeptides

Cite This Study

RPEP-09958·https://rethinkpeptides.com/research/RPEP-09958

APA

Apperley, Louise; Parkinson, Jennifer; Senniappan, Senthil. (2025). Liraglutide Treatment Improves Glycaemic Dysregulation, Body Composition, Cardiometabolic Variables and Uncontrolled Eating Behaviour in Adolescents with Severe Obesity.. Journal of clinical research in pediatric endocrinology, 17(1), 68-75. https://doi.org/10.4274/jcrpe.galenos.2024.2023-10-10

MLA

Apperley, Louise, et al. "Liraglutide Treatment Improves Glycaemic Dysregulation, Body Composition, Cardiometabolic Variables and Uncontrolled Eating Behaviour in Adolescents with Severe Obesity.." Journal of clinical research in pediatric endocrinology, 2025. https://doi.org/10.4274/jcrpe.galenos.2024.2023-10-10

RethinkPeptides

RethinkPeptides Research Database. "Liraglutide Treatment Improves Glycaemic Dysregulation, Body..." RPEP-09958. Retrieved from https://rethinkpeptides.com/research/apperley-2025-liraglutide-treatment-improves-glycaemic

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.